News Focus
News Focus
Followers 210
Posts 32738
Boards Moderated 1
Alias Born 06/30/2009

Re: frenchbroad post# 396071

Saturday, 01/28/2023 10:24:45 PM

Saturday, January 28, 2023 10:24:45 PM

Post# of 405181
This Regeneron model nonsense is just another version of this CEO's numerous attempts to connect this Company to other companies, real companies, without any real dots.
Back in 2016 he said, under the headline "Signs of Big Pharma Getting Back into the Antibiotics Business":
"In August 2014, Pfizer bought AstraZeneca’s antibiotics business for approximately $1.6 billion. In December 2014, Merck paid $8.4 billion to acquire Cubist, a market leader in antibiotic development. Its main antibiotic, Cubicin (Daptomycin), has generated over $1 billion in annual sales and is an antibiotic that Brilacidin has performed comparably to, both in the literature and in clinical trials, where Brilacidin went head-to-head with it in Phase 2 trials."
But so what? CTIX/IPIX has never done anything comparable for its investors. The companies he cited are real companies with approved drugs and real revenues.

As for Regeneron, consider this quote from it's S-3 Registration Statement filed in 2000:
"As of December 31,1999, we had 437 full-time employees, 82 of whom hold a Ph.D. and/or M.D. degree."
Regeneron has run and completed 106 Phase 3 trials.
Regeneron has never lost the confidence of its investors to the tune of a 99% loss in share price.

It takes some seriously huge testicules (en français) for this CEO to tell the public that he is using Regeneron as a business model. While it may be true that R**n had no approvals to show for the first 20 years, what they did have was several hundred million dollars provided by the likes of Amgen, Sanofil, Bayer, AstraZeneca, Proctor&Gamble and Astellas, companies that recognized the true potential of its development efforts. Hard cash, not lip service. CTIX/IPIX has yet to see a single serious Big Pharma step up similarly.

"Cellceutix has a robust pipeline with a full slate of ongoing and planned clinical trials. Our goal is to be the next Regeneron (REGN), a company built on novel science with the vision and strategy to grow exponentially."
Rubbish...some people believed it in 2015 and some still believe it. It's a naive belief.

No matter what it is or who commenced it, I'm against it!
....Groucho

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y